Skip to main content

About this Research Topic

Submission closed.

Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease characterized by an abnormal immune system and the production of a large number of autoantibodies against self-antigens. The clinical manifestations of SLE patients are complex and can involve multiple systems and multiple organs. As a chronic ...

Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease characterized by an abnormal immune system and the production of a large number of autoantibodies against self-antigens. The clinical manifestations of SLE patients are complex and can involve multiple systems and multiple organs. As a chronic inflammation disease, SLE can cause persistent inflammation if treated improperly, resulting in a significant disease burden for patients. At present, some drugs such as hydroxychloroquine, glucocorticoids, biological agents, etc. are widely used in the treatment of SLE, but the efficacy of those drugs is distinct in different patients. Therefore, further exploration of the characteristics and influencing factors in different populations plays a crucial role in the targeted therapy of SLE.
At present, the pathogenesis of SLE is still not fully elucidated. Many factors are related to SLE, such as genetics and environmental factors, which may play an important role in the pathogenesis of SLE. Due to the complex features of SLE, great challenges remain in the prevention, drug development, treatment, and prognostic management of SLE. Furthermore, using a variety of approaches and methods to explore the risk factors and pathogenesis of SLE is very important for the development of clinically targeted drugs and targeted therapy.
In this Research Topic, we aim to collect the latest research progress on the influencing factors and pathogenesis of SLE and summarize the latest knowledge and findings. We welcome the fusion of multiple approaches, methods, and fields to discover the latest progress in SLE, and provide new ideas for the prevention, drug development, and prognosis management of SLE.
Original Research, Reviews, and other types of articles are all welcome here. Research on recent breakthroughs in the discovery of new biomarkers in the physiopathology of SLE, important influencing factors found in population epidemiology, and their clinical significance are accepted.
Subtopics include but are not limited to the following:
1) Etiology in the pathogenesis of SLE;
2) Pathways in the pathogenic regulation of SLE;
3) Molecular mechanisms of SLE occurrence and development, including cellular and humoral factors and defects in tolerance and clearance mechanisms;
4) Research to explore the causal relationship between influencing factors and SLE;
5) Genetic, epigenetic, transcriptomic, protein, metabolomic, and environmental factors contributing to SLE development;
6) Research on biomarkers for early screening, prevention, and treatment of SLE;
7) Animal or population epidemiological studies on drug therapy targets and drug precision therapy;
8) Research on factors affecting drug efficacy;
9) Current or future research on SLE treatment strategies

Keywords: SLE


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Topic Editors

Loading..

Topic Coordinators

Loading..

Recent Articles

Loading..

Articles

Sort by:

Loading..

Authors

Loading..

total views

total views article views downloads topic views

}
 
Top countries
Top referring sites
Loading..

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.